CDK4 and chronic myelogenous leukemia, BCR-ABL1 positive: Schneeweiss-Gleixner et al. demonstrated that CDK4/6 inhibitors reduced CD4/CDK6 expression and blocked the proliferation and survival of BCR/ABL1 positive CML cells, highlighting the potential benefit of this treatment for CML patients [26].